RVMD earnings analysis
What we found in RVMD's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Revolution Medicines reported disappointing financial results for Q1 2026, with no revenue and an EPS loss of -2.29, missing consensus estimates of -1.84. The company incurred significant operational expenses, including $344 million in R&D costs, which pressure cash reserves to $1.9 billion, aligning with anticipated higher operating costs as guidance was updated to $1.7-1.8 billion for 2026. Significant risks remain in ongoing clinical developments and the broader market competition.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Q1 2026 EPS and Revenue Miss
- Reported EPS of -2.29 and revenue of $0, missing estimates of -1.84 and $6.1M.
- Massive R&D Spending
- R&D expenses reached $344 million in Q1 2026, significantly up from $206 million a year prior.
- Cash Reserves Total $1.9 Billion
- Cash, cash equivalents, and marketable securities fell from $2.0 billion at the end of 2025.
- Increased Operational Spend Guidance
- GAAP operating expenses guidance for 2026 was updated to $1.7 to $1.8 billion.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- $453.8M Net Loss in Q1 2026
- The company incurred a net loss of $453.8 million for the quarter, significantly impacting liquidity.
- Cash Position Declining
- Decline in cash reserves to $1.9 billion raises concerns about future funding for operations.
- Challenging Regulatory Environment Ahead
- The uncertainty in FDA approvals and the recent focus on drug pricing reforms could affect market operations.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-2.29
What they said about what is next.
2026 GAAP operating expenses guidance updated to a range of $1.7 to $1.8 billion.
The filing reads worse than the one before it.
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing RVMD makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever